SCHEMBL7632072

SCHEMBL7632072

O=C(CCc1ccc(O)cc1)C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.53
CES1 P23141 4/20 0.51
ESR1 P03372 3/20 0.50
ESR2 Q92731 2/20 0.50
KDM4E B2RXH2 3/20 0.49
CYP19A1 P11511 2/20 0.49
ALDH1A1 P00352 2/20 0.49
CYP2C19 P33261 2/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
MEN1 O00255 1/20 0.49
SLC16A3 O15427 1/20 0.49
LMNA P02545 1/20 0.49
TTR P02766 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 1/20 0.49
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10431233 0.89 FAAH (0.63) FAAHCES1ESR1ESR2
SCHEMBL10431223 0.87 FAAH (0.71) FAAHCES1
SCHEMBL10431527 0.85 ESR1 (0.46) ESR1ESR2KDM4ECYP19A1ALDH1A1
SCHEMBL8258314 0.82 FAAH (0.51) FAAHCES1RECQL
SCHEMBL1274684 0.82 CES1 (0.73) FAAHCES1ALDH1A1HDAC2HDAC8
SCHEMBL8980106 0.80 CYP24A1 (0.51) ESR1ESR2KDM4ECYP19A1ALDH1A1
SCHEMBL23512765 0.79 FAAH (0.57) FAAHCES1ALDH1A1CYP2C19HDAC2
SCHEMBL583919 0.79 FFAR1 (0.65) FAAHCES1HDAC2HDAC8LMNA
SCHEMBL10388813 0.79 FAAH (0.49) FAAHCES1
SCHEMBL10431529 0.79 CES1 (0.67) CES1ESR1ESR2LMNACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12372525-B2 Methods and kits for the diagnosis of influenza BECTON, DICKINSON AND COMPANY (US) 2025-07-29 US claimed
US-20220146514-A1 METHODS AND KITS FOR THE DIAGNOSIS OF INFLUENZA BECTON, DICKINSON AND COMPANY 2022-05-12 US claimed
CN-108663518-B Method and kit for influenza diagnosis 贝克顿·迪金森公司 2022-03-11 CN claimed
US-11209433-B2 Methods and kits for the diagnosis of influenza BECTON, DICKINSON AND COMPANY (US) 2021-12-28 US claimed
US-20190339272-A1 METHODS AND KITS FOR THE DIAGNOSIS OF INFLUENZA BECTON, DICKINSON AND COMPANY 2019-11-07 US claimed
US-12372525-B2 Methods and kits for the diagnosis of influenza BECTON, DICKINSON AND COMPANY (US) 2025-07-29 US disclosed
US-20240385182-A1 MASKED FLUOROGENIC LIPID COMPOUNDS, LIPID PARTICLES COMPRISING THE SAME, AND METHODS OF USE THEREOF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2024-11-21 US disclosed
US-20220146514-A1 METHODS AND KITS FOR THE DIAGNOSIS OF INFLUENZA BECTON, DICKINSON AND COMPANY 2022-05-12 US disclosed
US-20220146514-A1 METHODS AND KITS FOR THE DIAGNOSIS OF INFLUENZA BECTON, DICKINSON AND COMPANY 2022-05-12 US disclosed
CN-108663518-B Method and kit for influenza diagnosis 贝克顿·迪金森公司 2022-03-11 CN disclosed
US-11209433-B2 Methods and kits for the diagnosis of influenza BECTON, DICKINSON AND COMPANY (US) 2021-12-28 US disclosed
US-11209433-B2 Methods and kits for the diagnosis of influenza BECTON, DICKINSON AND COMPANY (US) 2021-12-28 US disclosed
US-5188937-A Binding of signal antibody to antigen BECTON, DICKINSON AND COMPANY (US) 1993-02-23 US disclosed
EP-0501526-A2 Fluoroketones as blocked enzyme inhibitors for use in immunoassays Becton, Dickinson and Company (US) 1992-09-02 EP disclosed
US-4962024-A ADDING SECOND ENZYME AND BLOCKED FLUOROKETONE INHIBITOR OF THE SECOND ENZYME BECTON, DICKINSON AND COMPANY (US) 1990-10-09 US disclosed
EP-0369361-A2 Immunoassay on a preblocked solid surface Becton, Dickinson and Company (US) 1990-05-23 EP disclosed
EP-0369657-A2 Chromogenic substrate for esterase and immunoassay using same Becton, Dickinson and Company (US) 1990-05-23 EP disclosed
EP-0354548-A2 Signal enhancement in assay for an enzyme Becton, Dickinson and Company (US) 1990-02-14 EP disclosed
US-4835099-A Signal enhancement in immunoassay by modulation of enzymatic catalysis BECTON, DICKINSON AND COMPANY (US) 1989-05-30 US disclosed
EP-0271731-A2 Signal enhancement in immunoassay by inhibition of enzymatic catalysis Becton, Dickinson and Company (US) 1988-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12372525-B2 Methods and kits for the diagnosis of influenza NEU3, NEU1, ADA FAAH 1142/4885CES1 847/4885ESR1 3126/4885
US-11209433-B2 Methods and kits for the diagnosis of influenza NEU3, NEU1, ADA FAAH 1142/4885CES1 847/4885ESR1 3126/4885
US-20240385182-A1 MASKED FLUOROGENIC LIPID COMPOUNDS, LIPID PARTICLES COMPRISING THE SAME, AND METHODS OF USE THEREOF GPX4, LIPA, ABHD16A FAAH 467/4885CES1 382/4885ESR1 3588/4885
US-20190339272-A1 METHODS AND KITS FOR THE DIAGNOSIS OF INFLUENZA NEU3, NEU1, ADA FAAH 1142/4885CES1 847/4885ESR1 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.